drugset / Trial / NCT01284569
Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether the ALX-0061, a Nanobody targeting the receptor for interleukin 6 (IL6R), is safe and effective after single or multiple administrations to patients with rheumatoid arthritis (RA). Patients will receive different single or multiple doses of either placebo or ALX-0061.
Timeline
- Start
- 2011-03
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vobarilizumab | Protein / enzyme biologic | 0.3 mg/kg | Intravenous |
| Subject | Vobarilizumab | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | Vobarilizumab | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | Vobarilizumab | Protein / enzyme biologic | 6 mg/kg | Intravenous |
| Subject | Vobarilizumab | Protein / enzyme biologic | 8 mg/kg | Intravenous |